Buscar
Genmab A/S
GMABAñadir a la lista de seguimiento
26.579USD
-0.511-1.89%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
16.38BCap. mercado
20.02P/E TTM
Más Datos de Genmab A/S Compañía
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Información de Genmab A/S
Símbolo de cotizaciónGMAB
Nombre de la empresaGenmab A/S
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoVan De Winkel (Jan G.J)
Número de empleados2682
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 01
DirecciónCarl Jacobsens Vej 30
CiudadVALBY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísDenmark
Código postal2500
Teléfono4570202728
Sitio Webhttps://www.genmab.com/
Símbolo de cotizaciónGMAB
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoVan De Winkel (Jan G.J)
Ejecutivos de Genmab A/S
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
Por regiónUSD
Nombre
Ganancia
Proporción
Denmark
3.33B
89.41%
Japan
213.00M
5.73%
U.S.A
180.00M
4.84%
Netherlands
1.00M
0.03%
China
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
Estadísticas de accionistas
Actualizado: jue., 19 de feb
Actualizado: jue., 19 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
Otro
93.34%
Accionistas
Accionistas
Proporción
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
Otro
93.34%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
5.75%
Investment Advisor
3.72%
Hedge Fund
2.33%
Research Firm
0.24%
Bank and Trust
0.03%
Pension Fund
0.03%
Family Office
0.02%
Otro
87.88%
Participación institucional
Actualizado: dom., 5 de abr
Actualizado: dom., 5 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
564
74.31M
12.10%
-2.99M
2025Q4
539
65.54M
10.64%
-9.83M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Orbis Investment Management Ltd.
14.42M
2.34%
+3.34M
+30.15%
Dec 31, 2025
AllianceBernstein L.P.
10.88M
1.77%
-76.82K
-0.70%
Dec 31, 2025
Paradigm BioCapital Advisors LP
7.04M
1.14%
+3.22M
+84.44%
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
4.98M
0.81%
+1.33M
+36.64%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
0.58%
+976.03K
+37.46%
Dec 31, 2025
Renaissance Technologies LLC
3.49M
0.57%
+671.31K
+23.79%
Dec 31, 2025
Harding Loevner LP
3.37M
0.55%
-114.34K
-3.28%
Dec 31, 2025
Parametric Portfolio Associates LLC
1.69M
0.27%
+109.58K
+6.93%
Dec 31, 2025
First Trust Advisors L.P.
1.34M
0.22%
-352.12K
-20.87%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
679.38K
0.11%
+256.44K
+60.63%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
Ver más
Tema Oncology ETF
Proporción4.2%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.02%
WisdomTree BioRevolution Fund
Proporción1.31%
iShares Biotechnology ETF
Proporción1.15%
AB Disruptors ETF
Proporción0.69%
JPMorgan Healthcare Leaders ETF
Proporción0.28%
First Trust NASDAQ BuyWrite Income ETF
Proporción0.26%
ProShares Ultra Nasdaq Biotechnology
Proporción0.12%
Invesco Nasdaq Biotechnology ETF
Proporción0.12%
ActivePassive International Equity ETF
Proporción0.12%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
